The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis

Abstract Background The predictive role of blood-based tumor mutation burden (bTMB) for selecting advanced nonsmall cell lung cancer (NSCLC) patients who might benefit from immune checkpoint inhibitors (ICIs) is still under debate. Therefore, the purpose of this meta-analysis was to evaluate the eff...

Full description

Bibliographic Details
Main Authors: He Ba, Lei Liu, Qiang Peng, Jie Chen, Yao-dong Zhu
Format: Article
Language:English
Published: BMC 2021-11-01
Series:BMC Cancer
Subjects:
PD-1
PD-L1
NSCLC
Tumor mutation burden
Blood
Lung cancer
Online Access:https://doi.org/10.1186/s12885-021-08924-z

Internet

https://doi.org/10.1186/s12885-021-08924-z

Similar Items